Celltrion Pharm, Inc. Sustainability Profile
Celltrion Pharm, Inc., a leading biopharmaceutical company headquartered in South Korea (KR), has established itself as a key player in the global healthcare industry since its founding in 2002. With a strong focus on the development and manufacturing of biosimilars and innovative therapeutics, Celltrion operates extensively across major markets, including Europe, the United States, and Asia. The company is renowned for its core products, which include monoclonal antibodies and biosimilars that offer cost-effective alternatives to expensive biologics. Celltrion's commitment to quality and innovation has positioned it as a trusted name in the biopharmaceutical sector, achieving significant milestones such as the successful launch of its flagship biosimilar, Remsima. With a robust pipeline and a dedication to advancing healthcare solutions, Celltrion Pharm continues to make strides in improving patient outcomes worldwide.
DitchCarbon Score
How does Celltrion Pharm, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celltrion Pharm, Inc.'s score of 30 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celltrion Pharm, Inc., headquartered in South Korea (KR), currently does not have available emissions data for the most recent year. As a current subsidiary of Celltrion, Inc., any potential emissions data would be inherited from this parent company. However, no specific carbon emissions figures or reduction targets have been disclosed for Celltrion Pharm, Inc. The company has not outlined any specific climate commitments or reduction initiatives, nor does it appear to have set Science-Based Targets (SBTi) or participated in the Carbon Disclosure Project (CDP) at this level. As such, there are no reported achievements in emissions reduction or climate action strategies. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon neutrality, but specific commitments or data from Celltrion Pharm, Inc. remain unspecified at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 16,864,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 31,667,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
How Carbon Intensive is Celltrion Pharm, Inc.'s Industry?
How Carbon Intensive is Celltrion Pharm, Inc.'s Location?
Celltrion Pharm, Inc.'s Scope 3 Categories Breakdown
A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 31% of total emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Celltrion Pharm, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Celltrion Pharm, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
